Key Takeaways (4-6 bullets, will render as highlighted box)
- The standard semaglutide titration is 0.25 mg weekly for 4 weeks, 0.5 mg weekly for 4 weeks, then increases every 4 weeks to a maximum of 2.4 mg weekly. Brand-name Wegovy follows this schedule exactly. Most compounded protocols mirror it.
- The titration exists to reduce GI side effects. The STEP 1 trial (Wilding et al., NEJM 2021) showed nausea peaked during dose escalation and faded as patients adapted, with about 4.5% of patients discontinuing for GI reasons.
- Unit conversions depend on your compounded vial's concentration. At the most common 2.5 mg/mL concentration, a 0.25 mg dose equals 10 units on a U-100 syringe. At 1 mg/mL it's 25 units. Always read the label, never assume.
- Holding the current dose for an extra 2 to 4 weeks is standard practice when side effects are intolerable. Skipping ahead to a higher dose to "catch up" is not standard and increases adverse event risk.
- This article is educational. Your clinician sets your dose. Self-adjusting up or down without provider input is not advised.
Direct answer (40-60 words)
The standard semaglutide dosing schedule is 0.25 mg weekly (weeks 1-4), 0.5 mg weekly (weeks 5-8), 1 mg weekly (weeks 9-12), 1.7 mg weekly (weeks 13-16), then 2.4 mg weekly maintenance from week 17 onward. Each step is a 4-week increase to allow the body to adapt and minimize nausea, vomiting, and diarrhea.
Table of contents
- The standard semaglutide titration schedule
- Brand-name Wegovy vs Ozempic dosing chart
- Compounded semaglutide unit conversions
- What to do if side effects appear during titration
- When to skip a dose increase
- Maintenance dose and long-term schedule
- Missed dose protocol
- Switching from semaglutide to tirzepatide (or vice versa)
- Stopping semaglutide and dose tapering
- FAQ
- Sources
- Footer disclaimers
The standard semaglutide titration schedule
Semaglutide titration is built around four-week steps. The schedule was established in the STEP and SUSTAIN clinical trial programs and has been adopted essentially unchanged by both brand-name and compounded protocols.
Get pre-measured GLP-1 doses shipped to your door
No mixing, no guesswork. FormBlends medications come ready to inject with clear dosing instructions.
Start Free Assessment →| Phase | Weeks | Weekly dose | Purpose |
|---|---|---|---|
| Initiation | 1-4 | 0.25 mg | Tolerance check, tissue exposure begins |
| Step 1 | 5-8 | 0.5 mg | First true therapeutic dose |
| Step 2 | 9-12 | 1.0 mg | Mid-range dose, often where weight loss accelerates |
| Step 3 | 13-16 | 1.7 mg | Sub-maximum, optional pause point if side effects |
| Maintenance | 17+ | 2.4 mg | Target dose for chronic weight management |
The 0.25 mg starting dose is sub-therapeutic on purpose. It exposes the body to the drug long enough to start adapting receptor sensitivity and gastric motility patterns, without delivering a dose large enough to produce strong nausea in most patients. Significant weight loss isn't expected during weeks 1 to 4. Patients who measure weight weekly during this phase often see flat or slightly increased numbers, which is normal.
The first real therapeutic dose is 0.5 mg starting in week 5. Most patients notice meaningful appetite suppression and early weight loss during weeks 5 to 8. The half-life of semaglutide is about 7 days, so steady-state plasma levels at any given dose are reached after roughly 4 to 5 weeks at that dose, which is why each titration step lasts 4 weeks rather than 1 or 2.
The maintenance dose of 2.4 mg weekly is the target for chronic weight management. Some patients respond well at lower doses (1.0 or 1.7 mg) and never need to escalate further. Others reach 2.4 mg and find that's where weight loss plateaus. The clinical trial data supports 2.4 mg as the most effective dose, but individual response varies.
Brand-name Wegovy vs Ozempic dosing chart
Wegovy is FDA-approved for chronic weight management. Ozempic is FDA-approved for type 2 diabetes. The two products are the same molecule (semaglutide) at slightly different dosing endpoints.
| Week | Wegovy (weight management) | Ozempic (type 2 diabetes) |
|---|---|---|
| 1-4 | 0.25 mg | 0.25 mg |
| 5-8 | 0.5 mg | 0.5 mg |
| 9-12 | 1.0 mg | 1.0 mg (often the maintenance dose for diabetes) |
| 13-16 | 1.7 mg | 1.0 mg or 2.0 mg |
| 17+ | 2.4 mg | 1.0 mg or 2.0 mg (max approved diabetes dose is 2.0 mg) |
The Ozempic maximum approved dose is 2.0 mg weekly. Wegovy's maximum is 2.4 mg weekly. The 0.4 mg difference is small but represents a regulatory distinction between the two indications. Patients prescribed Ozempic for off-label weight management typically stop at 2.0 mg.
Both products come in pre-filled multi-dose pens. Wegovy pens are single-dose disposable injectors at each dose strength. Ozempic pens are multi-dose pens that deliver the same concentration multiple times. The pen format means patients on brand-name semaglutide don't perform unit conversions. The dose is selected by a dial or printed on the pen.
Compounded semaglutide unit conversions
Compounded semaglutide comes in vials at varying concentrations, drawn into U-100 insulin syringes. The unit count for any given milligram dose depends on the concentration of your specific vial.
| Concentration | 0.25 mg | 0.5 mg | 1.0 mg | 1.7 mg | 2.4 mg |
|---|---|---|---|---|---|
| 1 mg/mL | 25 units (0.25 mL) | 50 units (0.50 mL) | 100 units (1.00 mL) | 170 units (1.70 mL) | 240 units (2.40 mL) |
| 2 mg/mL | 12.5 units (0.125 mL) | 25 units (0.25 mL) | 50 units (0.50 mL) | 85 units (0.85 mL) | 120 units (1.20 mL) |
| 2.5 mg/mL | 10 units (0.10 mL) | 20 units (0.20 mL) | 40 units (0.40 mL) | 68 units (0.68 mL) | 96 units (0.96 mL) |
| 5 mg/mL | 5 units (0.05 mL) | 10 units (0.10 mL) | 20 units (0.20 mL) | 34 units (0.34 mL) | 48 units (0.48 mL) |
| 10 mg/mL | 2.5 units (0.025 mL) | 5 units (0.05 mL) | 10 units (0.10 mL) | 17 units (0.17 mL) | 24 units (0.24 mL) |
The 2.5 mg/mL concentration is the most common in compounded semaglutide. The math is reasonably clean: every 0.25 mg of drug corresponds to 10 units on a U-100 syringe. Patients using a 1 mg/mL vial will draw larger volumes (25 units for the starting dose), which is fine but can require a 1 mL barrel syringe rather than a 0.3 mL barrel.
To find your vial's concentration: read the label. Look for "X mg/mL" or "X mg / Y mL" (divide to get mg/mL). If only total milligrams are listed, the concentration is on the dispensing instructions or pharmacy paperwork. Don't guess. Switching pharmacies or receiving a refill can change the concentration even if the total milligram count looks the same.
For the full visual on drawing a dose with a U-100 syringe, see our unit conversion guide (the principles are identical for semaglutide and tirzepatide, only the milligram doses differ).
What to do if side effects appear during titration
GI side effects are the most common limiting factor during dose escalation. The STEP 1 trial (Wilding et al., NEJM 2021) reported the following adverse event rates at any point during 68 weeks of treatment:
| Side effect | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Nausea | 44.2% | 16.1% |
| Diarrhea | 31.5% | 15.9% |
| Vomiting | 24.8% | 6.6% |
| Constipation | 23.4% | 9.5% |
| Abdominal pain | 20.0% | 10.4% |
| Headache | 14.0% | 10.0% |
Most of these were mild to moderate and clustered around dose escalation periods. The clinical strategy when a patient hits intolerable side effects:
Step 1: Hold the current dose. Don't escalate to the next step on schedule. Stay at the current dose for an additional 2 to 4 weeks until the body adapts.
Step 2: Reduce if necessary. If the current dose itself isn't tolerable, drop back to the previous dose. Stay there for 4 weeks before attempting to escalate again.
Step 3: Adjust diet patterns. Smaller, more frequent meals. Reduced fat content (high-fat meals worsen GI side effects on GLP-1s). Avoid lying flat for 1 to 2 hours after eating.
Step 4: Antiemetic support. Some clinicians prescribe ondansetron 4 mg or metoclopramide as needed for nausea during titration. This is provider-dependent.
Step 5: Hydration and electrolytes. Diarrhea and vomiting can cause dehydration quickly on GLP-1s. Patients should aim for 2 to 3 L of water plus electrolyte supplementation if symptoms are pronounced.
The American Gastroenterological Association 2022 clinical practice update on GLP-1 GI side effects (Camilleri et al., Gastroenterology 2022) emphasizes that the four-week titration window exists for tolerance, and rushing it produces worse outcomes than completing it on schedule.
When to skip a dose increase
Holding the current dose past four weeks is standard, common, and not a setback. Reasons to hold:
- Persistent nausea or vomiting at the current dose that hasn't faded over the four weeks
- Significant weight loss already happening at the current dose (no clinical reason to push higher)
- Travel or schedule disruption that makes managing side effects on a new dose impractical
- Dehydration, illness, or surgery in the recent past
Reasons not to skip ahead (i.e., jump from 0.5 mg to 1.7 mg):
- Side effects compound and may become severe at the higher dose
- The body's adaptation to one dose doesn't translate fully to a higher dose without an intermediate step
- Insurance coverage and pharmacy fills typically follow the standard titration schedule, so a self-imposed jump may not be supported by the prescription
If you're impatient with weight loss results, the answer is usually to give the current dose another 4 weeks rather than to escalate. Most patients who escalate aggressively end up dropping back due to side effects.
Maintenance dose and long-term schedule
Once a patient reaches their target dose (typically 2.4 mg for weight management or 1.0 to 2.0 mg for type 2 diabetes), the schedule is once-weekly indefinitely. The STEP 4 trial (Rubino et al., JAMA 2021) showed that patients who continued semaglutide for 68 additional weeks after a 20-week run-in maintained their weight loss, while patients who switched to placebo regained an average of 6.9% of body weight.
A few practical points about long-term maintenance:
- Weekly dosing day. Most patients pick a consistent day of the week (e.g., Monday or Sunday). The injection can be moved by a few days without disrupting steady-state levels, but consistency helps with adherence.
- Time of day. Doesn't matter much pharmacokinetically. Some patients prefer evening dosing because peak nausea (when it occurs) coincides with sleep.
- Site rotation. Abdomen (avoiding 2 inches around the navel), front or outer thigh, or back of the upper arm. Rotate sites weekly to avoid lipohypertrophy.
- Storage. Refrigerate at 36 to 46°F. Don't freeze. After first use, most compounded vials are good for 28 days at refrigerated temperature.
A small percentage of patients (about 10% in trials) plateau at a given dose and don't see additional weight loss when escalated further. For these patients, holding at the lower effective dose is reasonable.
Missed dose protocol
The FDA-approved label for semaglutide gives a clear protocol:
- If less than 5 days have passed since the missed dose: take the missed dose as soon as remembered, then resume the regular schedule (continue with the next scheduled weekly injection).
- If 5 or more days have passed: skip the missed dose and resume with the next regularly scheduled weekly injection.
The 5-day window exists because semaglutide's half-life of about 7 days means meaningful drug levels persist for 1 to 2 weeks after a dose. A makeup injection within 5 days doesn't produce overdose-level peaks. Beyond 5 days, the next scheduled dose is close enough that a makeup is unnecessary.
Two missed doses in a row (more than two weeks since last injection) can cause partial loss of GI tolerance. Restarting at the previous dose is usually fine, but some clinicians recommend stepping down one dose for the first restart injection.
Switching from semaglutide to tirzepatide (or vice versa)
Patients sometimes switch between GLP-1 agonists during their treatment. Common reasons: tolerance issues with one molecule, supply availability, cost, or clinical response.
Switching from semaglutide to tirzepatide: typically restarts at the lowest tirzepatide dose (2.5 mg weekly) regardless of where the patient was on semaglutide. The reason is GI tolerance. Tirzepatide acts on both GLP-1 and GIP receptors, and the receptor profile is different enough that previous tolerance doesn't fully transfer.
Switching from tirzepatide to semaglutide: typically restarts at 0.5 mg weekly (skipping the 0.25 mg starter dose) since the patient has already been on a high-receptor-engagement regimen. Some clinicians start at 1.0 mg if the patient was at high tirzepatide doses.
Timing of the switch: wait one week after the last dose of the previous medication before starting the new one, to avoid stacking effects.
Stopping semaglutide and dose tapering
Stopping semaglutide is not as simple as stopping the injections. The drug clears the body slowly (5 half-lives = roughly 5 weeks for full clearance), and weight regain after stopping is well-documented.
The STEP 4 extension data showed that patients who stopped semaglutide regained roughly two-thirds of their lost weight within a year. Hunger and food preoccupation often return within 2 to 4 weeks of the last injection as plasma levels fall.
Tapering options:
Option 1: Direct stop. Last injection on the regular schedule. Plasma levels decline over 4 to 5 weeks. Some patients tolerate this well. Others find appetite returns sharply.
Option 2: Step-down taper. Drop one dose level (e.g., from 2.4 mg to 1.7 mg) for 4 weeks, then 1.0 mg for 4 weeks, then stop. This smooths the transition but isn't strictly necessary pharmacologically.
Option 3: Frequency taper. Continue the same dose but space injections to every 10 days, then every 14 days, then stop. This is non-standard and not well-validated, but some clinicians use it.
For most patients, Option 1 or 2 is sufficient. The long elimination phase means there's no withdrawal in the strict sense. The challenge is behavioral. Hunger returns and food noise resumes, which often drives weight regain.
FAQ
What's the standard semaglutide dosing chart? 0.25 mg weekly for weeks 1-4, 0.5 mg weekly for weeks 5-8, 1.0 mg weekly for weeks 9-12, 1.7 mg weekly for weeks 13-16, and 2.4 mg weekly maintenance from week 17 onward. Each step is 4 weeks to allow tolerance to develop.
Why does semaglutide titrate so slowly? The slow titration reduces GI side effects (nausea, vomiting, diarrhea) and gives the body time to adapt to slowed gastric emptying. The STEP 1 trial demonstrated that the 4-week step interval kept discontinuation rates from GI side effects to about 4.5%.
How many units of compounded semaglutide is 0.25 mg? At the most common 2.5 mg/mL concentration, 0.25 mg equals 10 units on a U-100 insulin syringe. At 1 mg/mL it's 25 units. At 5 mg/mL it's 5 units. Always check your vial's concentration on the label.
Can I skip the 0.25 mg starter dose? No, not without a clinical reason. The starter dose is for tolerance, not effect. Skipping ahead increases nausea and vomiting risk. The only common scenario for starting higher is switching from a previous GLP-1, where some baseline tolerance carries over.
Is the dosing the same for compounded and brand-name semaglutide? The milligram doses are the same. The delivery format differs. Brand-name pens dial in the dose. Compounded vials require unit conversion based on the vial's concentration.
What if I miss a dose? If less than 5 days have passed, take it as soon as remembered and continue the schedule. If 5 or more days have passed, skip it and resume with the next scheduled dose. Don't double up.
How long until I see weight loss? Most patients see appetite suppression starting in week 5 (the first 0.5 mg dose). Measurable weight loss usually starts in weeks 6 to 8. The STEP 1 trial saw average 14.9% body weight loss at 68 weeks on 2.4 mg.
What's the maximum semaglutide dose? 2.4 mg weekly is the FDA-approved maximum for Wegovy (chronic weight management). 2.0 mg is the FDA-approved maximum for Ozempic (type 2 diabetes). Compounded protocols generally follow the 2.4 mg ceiling.
Should I increase the dose if I'm not losing weight? Discuss with your provider. Sometimes more time at the current dose is appropriate. Sometimes escalation is the right call. Self-adjusting dose without clinician input is not advised.
What if I have severe nausea on the starting dose? Hold the starting dose for an additional 2 to 4 weeks. If still intolerable, contact your provider. Some patients require dose reduction to 0.125 mg or fractional doses during the first month. This is a clinical decision, not a self-managed one.
Can I take semaglutide injections every two weeks instead of weekly? The half-life of semaglutide supports weekly dosing. Every-two-week dosing produces lower trough levels and reduced effect. Weekly is the validated schedule and the one your prescription is written for.
What's the difference between Wegovy and Ozempic dosing? Same molecule, slightly different maximum. Wegovy goes to 2.4 mg weekly for weight management. Ozempic goes to 2.0 mg weekly for type 2 diabetes. The titration steps for the first 12 weeks are identical.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
- Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight (STEP 3). JAMA. 2021;325(14):1403-1413.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
- Camilleri M, Acosta A. Combination therapies for obesity. Metab Syndr Relat Disord. 2018;16(8):390-394.
- American Gastroenterological Association. Clinical practice update: gastrointestinal effects of GLP-1 receptor agonists. Gastroenterology. 2022;163(2):473-488.
- U.S. Food and Drug Administration. Wegovy (semaglutide injection) prescribing information. 2024 revision.
- U.S. Food and Drug Administration. Ozempic (semaglutide injection) prescribing information. 2024 revision.
- United States Pharmacopeia. General Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. USP, 2024 revision.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Brand names are referenced for educational comparison only.